#behavioral interventions

#behavioral interventions

Primary care doctors are facing an influx of requests for anti-obesity drugs, including from patients who may not necessarily need them.

The demand for GLP-1 agonist drugs, such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound, is expected to increase after new data shows their potential in reducing heart problems.

There is a need for balanced consideration of other treatments and interventions before resorting to these drugs, as not everyone may require them. [ more ]

Primary care doctors are facing an influx of requests for anti-obesity drugs, including from patients who may not necessarily need them.

The demand for GLP-1 agonist drugs, such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound, is expected to increase after new data shows their potential in reducing heart problems.

There is a need for balanced consideration of other treatments and interventions before resorting to these drugs, as not everyone may require them. [ more ]

Primary care doctors are facing an influx of requests for anti-obesity drugs, including from patients who may not necessarily need them.

The demand for GLP-1 agonist drugs, such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound, is expected to increase after new data shows their potential in reducing heart problems.

There is a need for balanced consideration of other treatments and interventions before resorting to these drugs, as not everyone may require them. [ more ]